Fate Therapeutics Inc., a biopharmaceutical company focused on developing iPSC-derived cellular immunotherapies, has announced new employee compensation terms involving stock options and restricted stock units (RSUs). As of September 2, 2025, the company has granted non-qualified stock options to a newly-hired employee, allowing the purchase of 45,000 shares at $1.03 per share. Additionally, RSUs representing 63,000 shares have been awarded to two new employees. The stock options and RSUs will vest over four years, with an initial 25% vesting after one year and the remainder vesting in equal monthly or annual installments.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fate Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9522720-en) on September 03, 2025, and is solely responsible for the information contained therein.